Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia

被引：178

作者：

Aydemir, H. ^{[1
]}

Akduman, D. ^{[1
]}

Piskin, N. ^{[1
]}

Comert, F. ^{[2
]}

Horuz, E. ^{[1
]}

Terzi, A. ^{[2
]}

Kokturk, F. ^{[3
]}

Ornek, T. ^{[4
]}

Celebi, G. ^{[1
]}

机构：

[1] Bulent Ecevit Univ, Fac Med, Dept Infect Dis & Clin Microbiol, TR-67600 Zonguldak, Turkey

[2] Bulent Ecevit Univ, Fac Med, Dept Microbiol, TR-67600 Zonguldak, Turkey

[3] Bulent Ecevit Univ, Fac Med, Dept Biostat, TR-67600 Zonguldak, Turkey

[4] Bulent Ecevit Univ, Fac Med, Dept Pulm Dis, TR-67600 Zonguldak, Turkey

来源：

EPIDEMIOLOGY AND INFECTION | 2013年 / 141卷 / 06期

关键词：

Acinetobacter baumannii; adverse drug reaction; colistin; ventilator-associated pneumonia; CRITICALLY-ILL PATIENTS; IN-VITRO ACTIVITIES; PSEUDOMONAS-AERUGINOSA; NOSOCOMIAL INFECTIONS; INTRAVENOUS COLISTIN; INHALED COLISTIN; RENAL-FAILURE; POLYMYXIN-B; PHARMACOKINETICS; THERAPY;

D O I：

10.1017/S095026881200194X

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The aim of this study was to compare the responses of colistin treatment alone vs. a combination of colistin and rifampicin in the treatment of ventilator-associated pneumonia (VAP) caused by a carbapenem-resistant A. baumannii strain. Forty-three patients were randomly assigned to one of two treatment groups. Although clinical (P=0.654), laboratory (P=0.645), radiological (P=0.290) and microbiological (P=0.597) response rates were better in the combination group, these differences were not significant. However, time to microbiological clearance (3.1+/-0.5 days, P=0.029) was significantly shorter in the combination group. The VAP-related mortality rates were 63.6% (14/22) and 38.1% (8/21) for the colistin and the combination groups (P=0.171), respectively. Our results suggest that the combination of colistin with rifampicin may improve clinical and microbiological outcomes of VAP patients infected with A. baumannii.

引用

页码：1214 / 1222

页数：9

共 32 条

[1] CLINICAL PHARMACOKINETICS OF RIFAMPICIN [J].

ACOCELLA, G .

CLINICAL PHARMACOKINETICS, 1978, 3 (02) :108-127

[2] Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia [J].

不详 .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (04) :388-416

[3]

[Anonymous], 2011, Performance standards for antimicrobial disk susceptibility tests

[4]

approved standard M2-A11, V11th

[5]

[Anonymous], WIENER KLIN WOCHENSC

[6] Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections [J].

Bassetti, M. ;

Repetto, E. ;

Righi, E. ;

Boni, S. ;

Diverio, M. ;

Molinari, M. P. ;

Mussap, M. ;

Artioli, S. ;

Ansaldi, F. ;

Durando, P. ;

Orengo, G. ;

Pallavicini, F. Bobbio ;

Viscoli, C. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) :417-420

[7]

DEVLIEGER H, 1977, ACTA PAEDIATR BELG, V30, P179

[8]

Durmaz R, 2009, JPN J INFECT DIS, V62, P372

[9] Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin:: A comparison with imipenem-susceptible VAP [J].

Garnacho-Montero, J ;

Ortiz-Leyba, C ;

Jiménez-Jiménez, FJ ;

Barrero-Alodóvar, AE ;

García-Garmendia, JL ;

Bernabeu-Witteli, M ;

Gallego-Lara, SL ;

Madrazo-Osuna, J .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) :1111-1118

[10] Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients [J].

Garonzik, S. M. ;

Li, J. ;

Thamlikitkul, V. ;

Paterson, D. L. ;

Shoham, S. ;

Jacob, J. ;

Silveira, F. P. ;

Forrest, A. ;

Nation, R. L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) :3284-3294

← 1 2 3 4 →